KMO and early-onset autosomal dominant Alzheimer disease: Nonetheless, this could be in line with a study reporting that a non‐blood–brain barrier‐penetrating KMO inhibitor has beneficial effects on both peripheral and central phenotypes in an Alzheimer’s disease mouse model [24].